 |
||||
InvestorsSV Life SciencesSV Life Sciences was started in London as Schroder Ventures Life Sciences in 1993 as part of the Schroder Ventures Group. The company's first fund closed in 1994 raising $100m. SV Life Sciences now has four funds with current committed capital of more than $900m. Its team of 29 professionals are located in offices in Boston, London and San Francisco. SV Life Sciences became independent of the Schroder Ventures Group in 2001, and in January 2005 changed its name to SV Life Sciences to reflect independent ownership. SV Life Sciences provides finance to businesses at all stages of development and across the human life sciences sector. These sectors range from biotechnology & pharmaceuticals to medical devices & instruments, to healthcare information technology and services. SV Life Sciences currently advises or manages five funds with capital commitments of approximately $1.6 billion which primarily invest amounts of between $1m and $20m in North America and Europe, but will consider innovative investments in other regions. Our team of 28 professionals has a diverse, complimentary set of skills and experience that allow us to tailor a team to work with almost any life sciences business.
HBM PartnersHBM Partners AG, founded in 2001, is one of the world’s leading investment advisory groups in the sectors of biotechnology, emerging pharma and medical technology. The group invests globally in private, as well as public companies. The HBM team of professionals has extensive experience in drug and medical device development and international operations. Currently, HBM Partners AG manages and advises several investment entities with assets of over US$1 billion. Out of HBM’s private equity portfolio 23 companies have gone public and 8 companies were sold to strategic buyers.
Novo A/SNovo A/S is the holding company of the Novo Group, and is wholly owned by the Novo Nordisk Foundation. Novo A/S was established in 1999 to manage the assets of the Foundation and actively make investments on behalf of the Foundation. The Novo Ventures team consists of six Partners in Copenhagen, one in London and two in San Francisco. With an evergreen structure, Novo A/S annually invests approximately $ 80-100 million in venture capital into private life sciences companies, and thus acts at a pace comparable to a traditional $350-400 million fund. In total Novo A/S has more than $ 10 billion under management, which includes significant shareholdings in the independently operating and publicly listed companies Novo Nordisk A/S and Novozymes A/S.
|
||||
|
||||
